Maher D,Raviglione M.Global epidemiology of tuberculosis[J].Clin Chest Med,2005,26(2):167-182.
[2]
D Young,C Dye.The development and impact of tuberculosis vaccines[J].Cell,2006,124(4):683-6837.
[3]
袁伟,秦川.结核疫苗研究进展[J].中国比较医学杂志,2011,21(2):60-64.
[4]
Brooks JV,Frank.AA,Keen MA,et al.Boosting vaccine for tuberculosis[J].Infect Immun,2001,69(4):2714-2717.
[5]
YA Skeiky,MR AlderSon PJ Ovendale,et al.Differential immuneres responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine,Mtb72F,delivered as naked DNA or recombinant protein[J].J Immunol,2004,172(12):7618-7628.
[6]
Billeskov R,Grandal MV,Poulsen C,et al.Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4,BCG or infection with Mycobacterium tuberculosis[J].Eur J Immunol,2010,40(5):1342-1354.
[7]
Hervas-Stubbs S.High frequency of CD4+T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection[J].Infect Immun,2006,74(6):3396-3407.
[8]
Skjot RL.Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9,which constitute a subfamily of the esat-6 gene family[J].Infect Immun,2002,70(10):5446-5453.
[9]
Britton WJ,Palengira V.Improving vaccines against tuberculosis[J].Immunal Cell Biol,2003,81(1):34-45.
[10]
Bentley-Hibbert SI,Quan X,NewmanT,et al.Pathophysiology of antigen 85 in patients with active tuberculosis:antigen 85 circulates as complexes with fibronectin and immunoglobulin [J].Infect Immun,1999,67(2):581.
